| Annual · values | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -106.36 M EUR | -104.18 M EUR | -85.68 M EUR | -19.65 M EUR | -29.45 M EUR | 49.54 M EUR |
| Depreciation & Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — |
| Capital Expenditures | — | — | — | — | — | — |
| Cash Flow from Investing | — | — | — | — | — | — |
| Cash Flow from Financing | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — |
| Free Cash Flow | -114.00 M EUR | -105.59 M EUR | -90.44 M EUR | -19.84 M EUR | -30.53 M EUR | 48.72 M EUR |
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The company harnesses the body's immune system to target tumor cells through its proprietary innate cell engager (ICE) technology, including the TandAb platform that produces tetravalent, bispecific, fully human antibodies with enhanced binding properties and stability compared to traditional monoclonal antibodies. Its pipeline features key product candidates such as AFM13, which targets CD30-positive lymphomas including relapsed/refractory peripheral T-cell lymphoma and Hodgkin lymphoma; AFM24 for advanced EGFR-expressing solid tumors; and preclinical programs like AFM26 for multiple myeloma, AFM28 for acute myeloid leukemia, and AFM32 for solid tumors. Affimed N.V. conducts clinical studies in immuno-oncology, enrolling patients in registration-directed and dose escalation/expansion trials. The company also maintains collaborations with partners like Genentech to advance product candidates for various cancers. Founded in 2000 and headquartered in Mannheim, Germany, Affimed N.V. operates in the biotechnology sector, emphasizing targeted therapies for life-threatening diseases with high unmet medical needs.